The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

2020329 citationsJournal Articlebronze Open Access

Authors

Steven P. Treon · Brigham and Women's Hospital

Jorge J. Castillo · Brigham and Women's Hospital

Alan P Skarbnik · Novant Health

Jacob D. Soumerai · Harvard University

Irene M. Ghobrial · Brigham and Women's Hospital

Maria Luisa Guerrera · Brigham and Women's Hospital

Kirsten Meid

Abstract

Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Galectins and Cancer Biology PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Blood

Volume 135, Issue 21, pp. 1912-1915

DOI: 10.1182/blood.2020006288

Field-Weighted Citation Impact: 36.53